Regeneron Pharmaceuticals Inc (REGN)

Operating profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Operating income (ttm) US$ in thousands 4,047,100 4,221,000 4,333,700 4,427,100 4,738,900 6,231,800 6,855,300 9,092,600 8,946,800 7,474,100 6,680,000 3,989,200 3,576,600 3,085,300 2,770,700 2,429,900 2,209,800 2,252,200 2,140,600 2,447,200
Revenue (ttm) US$ in thousands 13,044,200 13,025,200 12,601,200 12,306,100 12,113,500 13,654,100 14,171,800 16,451,800 16,014,400 13,499,700 12,328,800 9,147,000 8,455,000 8,201,600 7,974,500 7,957,900 7,839,900 7,598,200 7,213,600 6,889,000
Operating profit margin 31.03% 32.41% 34.39% 35.97% 39.12% 45.64% 48.37% 55.27% 55.87% 55.36% 54.18% 43.61% 42.30% 37.62% 34.74% 30.53% 28.19% 29.64% 29.67% 35.52%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $4,047,100K ÷ $13,044,200K
= 31.03%

Regeneron Pharmaceuticals, Inc.'s operating profit margin has shown a declining trend over the past eight quarters, indicating potential challenges in managing operating expenses relative to revenue generation. The company's operating profit margin decreased from 55.10% in Q1 2022 to 32.26% in Q4 2023. This downward trajectory suggests a decrease in the efficiency of converting revenue into profits, which could be attributed to factors such as rising costs or pricing pressures in the pharmaceutical industry. It is important for the company to closely monitor and address the underlying factors driving this decline to ensure sustainable profitability and operational efficiency in the future.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Operating Profit Margin (Quarterly Data)